Quantcast

Latest QIAGEN N.V. Stories

2014-10-29 16:28:58

VENLO, The Netherlands, October 29, 2014 /PRNewswire/ -- - Achieved Q3 2014 targets: Adjusted net sales of $336.8 million (+4% CER); adjusted operating income of $84.8 million, a 25% margin; and adjusted EPS of $0.27 - Adjusted net sales rise approximately 10% CER excluding U.S. HPV business - Growth drivers contribute about 30% of total sales, delivering more than 20% CER growth and creating solid foundation for...

2014-10-28 16:27:44

HILDEN, Germany and TOKYO, October 28, 2014 /PRNewswire/ -- - First two programs aim to create tests to aid in cancer treatment with Astellas compounds under development - QIAGEN Personalized Healthcare pipeline expands with novel assay targeting FGFR mutations - Partnership provides options for collaboration across therapeutic areas, sample types and testing technologies QIAGEN N.V. (NASDAQ: QGEN; Frankfurt...

2014-10-28 16:26:51

HILDEN, Germany and BARCELONA, Spain, October 28, 2014 /PRNewswire/ -- - New WHO guidelines launched for prevention include screening and treating for latent TB infection to avert progression to active disease, supporting the implementation of the Post-2015 strategy - QIAGEN will support implementation of new guidelines with awareness campaigns and educational programs, improved access to QuantiFERON(R)-TB Gold, research...

2014-10-17 16:24:46

SAN DIEGO and HILDEN, Germany, October 17, 2014 /PRNewswire/ -- - Translational research in cancer and other diseases will benefit from new capabilities being presented at the American Society of Human Genetics annual meeting - Volume of 250,000-plus DNA samples linked to Ingenuity(R) Knowledge Base greatly exceeds any comparable database - providing superior depth for genomic analysis - Ingenuity(R) Variant...

2014-10-10 12:24:46

VENLO, The Netherlands, October 10, 2014 /PRNewswire/ -- QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) today reconfirmed plans to release its report on results for the third quarter 2014 on Wednesday, October 29, at 21:00 Central European Time (CET) / 16:00 Eastern Time (ET). On the same day, a conference call is planned at 22:00 Central European Time (CET) / 17:00 Eastern Time (ET) that will include remarks by Peer M. Schatz, President and Chief Executive Officer, and...

2014-07-29 16:28:37

ReportsnReports.com offers "Microbial Identification Market Products (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic) Application (Pharmaceutical, Diagnostic, Environmental, Food & Beverages), End User (Detection, Characterization) - Global Forecasts to 2019" global research report in its store. NEW YORK, July 29, 2014 /PRNewswire-iReach/ -- The global microbial identification market is categorized on the basis of products, methods, applications, end users, and...

2014-07-29 16:26:30

VENLO, the Netherlands, July 29, 2014 /PRNewswire/ -- - Achieved Q2 2014 targets: Adjusted net sales of $331.2 million (+4% CER); adjusted operating income of $81.2 million and 25% operating margin; adjusted EPS of $0.26 CER - H1 2014 adjusted net sales rise approximately 8% CER excluding U.S. HPV tests, in line with full-year 2014 goal; H1 2014 free cash flow rises 28% to $77 million...

2014-07-28 04:21:34

HILDEN, Germany and LONDON, July 28, 2014 /PRNewswire/ -- - Collaboration aims to create and commercialize companion diagnostic using genomic data from plasma samples to guide the use of IRESSA for non-small cell lung cancer patients - New blood test will build on QIAGEN's FDA-approved therascreen EGFR test and is planned to run on Rotor-Gene Q, member of the QIAsymphony family of automated instruments -...

2014-07-24 16:26:56

HILDEN, Germany, and MARSEILLE, France, July 24, 2014 /PRNewswire/ -- - Exclusive global license from University of Tokyo enables development of QIAGEN assays for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, for blood cancers - Mutations of SF3B1 gene, to be targeted by new test, indicate favorable prognosis for patients with bone marrow disorders known as myelodysplastic syndromes - QIAGEN...

2014-07-15 16:27:35

GERMANTOWN, Maryland and HILDEN, Germany, July 15, 2014 /PRNewswire/ -- - QIAGEN introduces 14 new panels for targeted enrichment of up to 570 clinically-relevant genes, expands largest portfolio of panels for assessing cancer genes - GeneRead DNAseq V2 gene panels integrate with QIAGEN bioinformatics, allowing customization of assays and streamlined data analysis and interpretation for fast generation of valuable...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related